Thanks, Rohit. Good morning, everyone. We again delivered very strong results in the second quarter of 2023. GAAP net income for the quarter was $168 million, or $1.04 per diluted share, as compared to $1.25 per diluted share in the same period last year, and $1.08 per diluted share in the first quarter of 2023. Return on equity was 15.5%. Adjusted operating income was $178 million, or a $1.10 per diluted share, as compared to $205 million, or $1.26 per diluted share in the same period last year, and $176 million, or $1.08 per diluted share in the first quarter of 2023. Adjusted operating return on equity was 16.4%. Turning to revenue drivers. primary insurance-in-force increased in the second quarter to a new record of $258 billion, up $5 billion, or 2% sequentially, and up $20 billion, or 9% year-over-year. New insurance written of $15 billion was up $2 billion, or 15% sequentially, driven in part by higher originations and down $2 billion, or 14% year-over-year, driven by lower mortgage originations resulting from continued elevated interest rates. With elevated interest rates, persistency remained high at 84% in the second quarter, down 1 percentage point sequentially and up 4 percentage points year-over-year. Given that most of our insured portfolio has mortgage rates at or below 6%, and the expectation that interest rates will remain elevated in the short term, we anticipate continued strength and persistency, which is a positive for the future profitability of our insurance-in-force portfolio. Our base premium rate was 40.3 basis points, down 0.2 basis points sequentially, 2.2 basis points year-over-year and 0.7 basis points year-to-date. The rate of change in our base premium rate continues to narrow and is in line with our expectations. As a reminder, base premium rate is impacted by a variety of factors and can deviate from quarter-to-quarter. Our net earned premium rate also reflected lower single premium cancellations year-over-year. For the quarter, single premium cancellations were flat sequentially and contributed only $2 million of net earned premium, limiting its potential for meaningful future dilution. Investment income in the second quarter was $51 million, up $6 million, or 12% sequentially, and $15 million, or 42% year-over-year. The rise in interest rates and the current rate environment are favorable for our investment portfolio, as our new money yield for the quarter was over 5%. as of quarter end, unrealized losses in our investment portfolio increased by $32 million to $439 million. As I've mentioned, although we generally do not expect to realize these losses, we will act upon opportunities that are expected to generate the highest value at a given time. During the quarter, we identified assets that upon selling, generated a loss, but presented an opportunity for higher net investment income going forward. We'll continue to evaluate similar opportunities to maximize the value of our portfolio, but this does not change our view that our investment portfolio's unrealized loss position is materially non-economic. Revenue for the quarter were $278 million, down $3 million, or 1% sequentially, and up $4 million, or 1% year-over-year. Excluding the opportunistic investment trade just mentioned, which resulted in a $13 million loss in exchange for higher future investment income, revenues in the quarter were up $10 million, or a 3% sequentially and $17 million or a 6% year-over-year. Net premiums earned were $239 million, up $3 million or 1% sequentially and relatively flat year-over-year. The increase in net premiums earned sequentially was driven by strong IIF growth, partially offset by the lapse of older higher price policies, as compared to our NIW. Turning to credit. losses in the quarter were a benefit of $4 million, as compared to a benefit of $11 million last quarter and a benefit of $62 million in the second quarter of 2022. Our loss ratio for the quarter was negative 2%, compared to negative 5% last quarter and negative 26% in the second quarter of 2022. Our losses and loss ratio were primarily driven by favorable cure performance, which was above our expectations, resulting in a $63 million reserve release in the quarter. Included in the reserve release were delinquencies from the first half of 2022, which were reserved at a 10% claim rate. New delinquencies decreased sequentially to 9,200 from 9,600. Our new delinquency rate for the quarter was 1%, consistent with pre-pandemic levels and reflective of ongoing positive credit trends. We continue to book new delinquencies at an approximate 10% claim rate, reflecting our prudent and measured approach to reserving in this dynamic environment. total delinquencies in the second quarter decreased by approximately 500 to 18,100 as cures outpaced new delinquencies. The associated delinquency rate stayed flat at 1.9%, which is stabilizing near pre-pandemic levels. Turning to expenses. Operating expenses in the quarter were $55 million, relatively flat sequentially and down $7 million, or 11% year-over-year. The expense ratio for the quarter was 23%, flat to the first quarter of 2023 and below the 26% we reported a year ago. Our performance reflected the ongoing benefit of our cost reduction actions. We continue to expect costs for the full year to decline 6% year-over-year to $225 million. Moving to capital and liquidity. we continue to operate from a position of financial strength and flexibility. As Rohit referenced, this quarter, we executed our first quota share reinsurance transaction as part of our credit risk transfer program. The transaction secured coverage from a panel of highly-rated reinsurers covering approximately 13% of our current and expected new insurance written throughout 2023. We believe the inclusion of quota share reinsurance coverage into our CRT program provides incremental capacity on attractive terms at a time of volatility in the CRT market and serves as another proof point for the value of diversified capital sources. As of June 30, 2023, our CRT program provides $1.5 billion reduction to our PMIER's minimum required assets. Before moving on to a discussion of PMIERs and capital allocation, I wanted to take a minute on Enact Re. As Rohit discussed, we are very pleased to have launched Enact Re during the quarter. Enact Re is a Bermuda-based, wholly-owned subsidiary of EMICO and is classified as a non-exclusive affiliated reinsurer for PMIERs purposes. EMICO has initially contributed $250 million to Enact REIT, which serves as a reallocation of capital to Enact Re that will be used to support the initial 7.5% quota share of business from EMICO and our participation in transactions with the GSEs. The strength of our credit ratings is a key factor in our ability to successfully enter and participate in the GSE's CRT market. The quota share agreement with EMICO has provided the scale and efficiency to support our strong ratings and opportunities to pursue third-party risk on attractive terms. Over the long-term, we believe Enact Re will contribute to increasing our income and shareholder order value while preserving our dividend capacity. Additionally, we expect it to have a minimal impact on our expense structure, as evidenced by the fact that we have reaffirmed our expense guidance of $225 million for the year. We have structured Enact Re to be efficient from a ratings capital and expense perspective, and will take an intentional approach to growing the business that balances scaling it to optimize a return on capital with our disciplined approach to capital allocation and commitment to our core franchise. we intend to prudently build scale in this business and we'll continue to keep the market apprised of progress through time. Let me now shift gears to talk about PMIERs and capital allocation. Our PMIER's efficiency remains strong at 162%, or $2 billion above PMIER's requirements, compared to 164% or $2.1 billion in the first quarter of 2023. At quarter-end, we had $1.5 billion of PMIER's capital credit and $2.7 billion of seeded risk, provided by our third-party CRT program, which currently covers 90% of our risk in-force. Turning now to capital allocation. we remain committed to our prioritization framework, which balances prudently investing to strengthen and differentiate our platform, maintaining a strong balance sheet, and supporting our policyholders and returning capital to shareholders. I've already talked about Enact Re and our strong PMIER's position, which touch on the first two pillars. So, let me take a moment to speak to capital return. Yesterday, we announced that our board has approved a new $100 million share repurchase program. As with our prior program, Genworth will participate proportionately to their 81.6% ownership, ensuring their proportional ownership of Enact remains unchanged. We returned a total of $67 million to shareholders during the second quarter, consisting of our $26 million, or $0.16 per share quarterly dividend, which was increased 14% and share repurchases totaling $41 million. As of July 30, 2023, we have repurchased $71 million in stock and have $4 million remaining on our current $75 million share repurchase authorization. We are well-positioned to return capital to shareholders in 2023. And as Rohit mentioned, with a strong first half behind us, we are increasing our capital return guidance for the year to $300 million, up $50 million from 2022 levels through a combination of our quarterly dividend, share repurchases and a potential special dividend in the fourth quarter. In April, EMICO, our primary mortgage insurance operating company completed a distribution of $158 million that will be used to support our ability to return capital to shareholders and bolster financial flexibility. We had a strong quarter in an outstanding first half of 2023. We remain focused on prudently managing our risk, driving cost efficiencies and maintaining a strong balance sheet while executing against our capital allocation strategy. With that, I'll turn it back to Rohit.